Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial

JAMA

Volumn 281, Issue 14, 1999, Pages 1275-1281

  Johansen, Kirsten L ^a,b   Mulligan, Kathleen ^a   Schambelan, Morris ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; NANDROLONE; PLACEBO;

ACNE; ADULT; AGED; AMENORRHEA; ARTICLE; BODY COMPOSITION; CATABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEMATOMA; HUMAN; LEAN BODY WEIGHT; MALE; MALNUTRITION; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; NITROGEN BALANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0033553183     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.14.1275     Document Type: Article

References (40)

1. US Renal Data System. USRDS 1994 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1994.
2. Woodrow C, Oldroyd B, Turney J, Tompkins L, Brownjohn A, Smith M. Whole body and regional body composition in patients with chronic renal failure. Nephrol Dial Transplant. 1996;11:1613-1618.
3. Pollock C, Allen B, Warden R, et al. Total-body nitrogen by neutron activation in maintenance dialysis. Am J Kidney Dis. 1990;16:38-45.
4. Coles G. Body composition in chronic renal failure. QJM. 1972;41:25-47.
5. Hakim R, Levin N. Malnutrition in hemodialysis patients. Am J Kidney Dis. 1993;21:125-137.
6. Lazarus J. Nutrition in hemodialysis patients. Am J Kidney Dis. 1993;21:99-105.
7. Kopple J. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis. 1994;24:1002-1009.
8. Lowrie E, Lew N. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-482.
9. Mulligan K, Grunfeld C, Hellerstein M, Neese R, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab. 1993;77:956-962.
10. Tayek J, Brasel J. Growth hormone administration decreases urea nitrogen losses in malnourished cancer patients [abstract]. Clin Res. 1992;40:95A.
11. Manson JM, Wilmore D. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feeding. Surgery. 1986;100:188-197.
12. Ziegler T, Lazarus JM, Young L, Hakim R, Wilmore D. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol. 1991;2:1130-1135.
13. Schulman G, Wingard R, Hutchison R, Lawrence P, Hakim R. The effects of recombinant human growth hormone and intradialysis parenteral nutrition in malnourished hemodialysis patients. Am J Kidney Dis. 1993;21:527-534.
14. Ikizler T, Wingard R, Breyer J, Schulman G, Parker R, Hakim R. Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int. 1994;46:1178-1183.
15. Bhasin S, Storer T, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996; 335:1-7.
16. Sargent J. Control of dialysis by a single-pool urea model: the National Cooperative Dialysis Study. Kidney Int. 1983;13(suppl):S19-S25.
17. American College of Sports Medicine. Guidelines for Exercise Testing and Prescription. 4th ed. Philadelphia, Pa: Lea & Febiger; 1991.
18. Campbell A, Converse P, Rodgers W. The Quality of American Life. New York, NY: Russell Sage Foundation; 1976.
19. Bergner M, Bobbit R, Carter W, Gilson B. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981;19:787-805.
20. McNair D, Lorr M, Droppleman L. EITS Manual for the Profile of Mood States. San Diego, Calif: Educational and Industrial Testing Service; 1971.
21. Botero D, Danon M, Brown R. Symptomatic noninsulin-dependent diabetes mellitus during therapy with recombinant human growth hormone. J Pediatr. 1993; 123:590-592.
22. Kollind M, Adamson U, Lins P, Efendic S. Diabetogenic action of GH and cortisol in insulin-dependent diabetes mellitus: aspects of the mechanisms behind the Somogyi phenomenon. Horm Metab Res. 1987;19:156-159.
23. Lindholm D, Fisher J, Vieira J, Dombeck DH, Bemal G, Lerthora J. Clinical effects of oral fluoxymesterone in patients with dialysis-controlled uremia. Trans Am Soc Artif Intern Organs. 1973;19:475-483.
24. Hurley B, Seals D, Hagberg J, et al. High-density-lipoprotein cholesterol in bodybuilders v powerlifters: negative effects of androgen use. JAMA. 1984; 252:507-513.
25. Thompson P, Cullinane E, Sady S, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989;261:1165-1168.
26. Glazer G, Suchman A. Lack of demonstrated effect of nandrolone on serum lipids. Metabolism. 1994; 43:204-210.
27. Hendler E, Goffinet J, Ross S, Longnecker R, Bakovic V. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. N Engl J Med. 1974;291:1046-1051.
28. Teruel J, Lasuncion M, Rivera M, et al. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis. 1997;29:569-575.
29. Lippi G, Guidi G, Ruzzenente O, Braga V, Adam S. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Stand J Clin Lab Invest. 1997;57:507-512.
30. Cressman M, Heyka R, Paganini E, O'Neil J, Skibinski C, Hoff H. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992;86:475-482.
31. Kronenberg F, Utermann G, Dleplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. 1996; 27:1-25.
32. Bartens W, Nauck M, Schollmeyer P, Wanner C. Elevated lipoprotein(a) and fibrinogen levels [corrected] increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1996;16:27-33.
33. Avram M, Sreedhara R, Patel N, Chattoopadhyay J, Thu T, Fein P. Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patients? Adv Perit Dial. 1996;12:266-271.
34. Bradley J, Anderson J, Evans D, Cowley A. Impaired nutritive skeletal muscle blood flow in patients with chronic renal failure. Clin Sci. 1990;79:239-245.
35. Painter P, Messer D, Widener C, Zimmerman S. Response to graded exercise testing in patients treated with CAPD. Perit Dial Bull. 1984;4(suppl):S94-S97.
36. Painter P, Messer-Rehak D, Hanson P, Zimmerman S, Glass N. Exercise capacity in hemodialysis, CAPD, and renal transplant patients. Nephron. 1986; 42:47-51.
37. 2peak in patients with end-stage renal disease: on and off dialysis. Med Sci Sports Exerc. 1993;25:18-23.
38. Gutman R, Stead W, Robinson R. Physical activity and employment status of patients on maintenance dialysis. N Engl J Med. 1981;304:309-313.
39. Ifudu O, Paul H, Mayers I, et al. Pervasive failed rehabilitation in center-based maintenance hemodialysis patients. Am J Kidney Dis. 1994;23:394-400.
40. Churchill D, Torrance G, Taylor D, et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med. 1987; 10:14-20.